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Seniors are heavy users of medications. Despite strong
evidence that some medications are associated with an
increased risk of serious adverse consequences in seniors,
physicians prescribe, pharmacists dispense, plans pay and
seniors suffer. One such adverse consequence is a fall 
secondary to dizziness or instability of gait. A fall with a
resulting fracture is a leading cause of hospitalizations
and deaths of seniors.
OBJECTIVES: To advance the quality of its prescription
drug beneﬁt, a telecommunications company studied
whether taking prescription drugs both known or 
suspected of causing dizziness or instability of gait in
seniors increase the likelihood of fractures. The pre-
scription drugs studied included: propoxyphene and com-
binations; hydantoin anticonvulsants; benzodiazepines;
selective serotonin reuptake inhibitors; and tricyclic 
antidepressants.
METHODS: This analysis studied the rate of hip frac-
tures in a group of 35,264 members over a ﬁve-year
period from 1996 to 2000. Each member in the study
reached the age of 65 by January 1, 1996. Parametric
duration regression models were used to quantify the
impact of taking certain prescription drugs on the likeli-
hood of subsequently having a hip fracture and to control
for differences between study members with hip fractures
and those without.
RESULTS: Nearly 4% of the study population experi-
enced a hip fracture during the time period. Each addi-
tional year of age increased the likelihood of having a hip
fracture by 10.5%. Females were 73 percent more likely
than males to have a hip fracture. Members who took
amitriptyline were 48 percent more likely, and members
who took temazepam were 27 percent more likely to have
a subsequent hip fracture during the study period.
CONCLUSIONS: Amitriptyline and temazepam in-
creased the likelihood of hip fracture among Medicare-
eligible plan members. The telecommunications company
will use this evidence to reduce the use of these medica-
tions, when appropriate, by its members.
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The FDA has designated 23 pharmaceutical entities as
Narrow Therapeutic Index (NTI) drugs based on the
range between therapeutic and toxic dose levels. The
generic substitution of NTI drugs has been controversial
due to perceived bioequivalence problems.
OBJECTIVES: We examined the ambulatory generic 
NTI drug use and cost from 1996 through 1998 and com-
pared NTI drugs with non-NTI drugs in generic use. The
relationship between generic use and retail pricing was
explored.
METHODS: This study examined secondary data 
using 1996–1998 Medical Expenditure Panel Survey
(MEPS) data. MEPS provides nationally representative
estimates of health care use, expenditures, sources of
payment, and insurance coverage for the U.S. civilian
non-institutionalized population.
RESULTS: NTI drugs represent 7.0%, 6.3%, and 5.9%
of total annual prescriptions from 1996 to 1998, respec-
tively, which correspond to 6.1%, 5.2%, and 4.9% of
total prescription expenditures. Among multiple-sources
drugs, NTI drugs are more likely than non-NTI drugs to
be dispensed by brandname with odds ratios of 3.9, 3.4,
and 4.1 in 1996, 1997, and 1998, respectively (P < 0.05).
The median discount rates for non-NTI drugs are 0.35
and 0.32 for 1996 and 1997 compared to rates of 0.36
and 0.34 for NTI drugs. Accordingly, the realized savings
from generic NTI drugs were 249.2 and 265.3 million
dollars for 1996 and 1997. If NTI drugs had the same
generic use rates as non-NTI drugs, an additional 293.6
and 147.7 million dollars could have been saved. The dis-
count rates of generic drugs were positively associated
with use in both NTI and non-NTI drugs in 1996 with a
stronger effect in NTI drugs. The switch rates of NTI
drugs were not different from those of non-NTI drugs.
CONCLUSIONS: Generic NTI drugs were used at a
lower rate than non-NTI drugs from 1996 to 1998.
Increased generic NTI drugs use could lead to more
savings.
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OBJECTIVE: To examine the impact of two and three-
tiered prescription drug beneﬁts on medication adherence
rates among managed care patients with selected chronic
conditions.
